1-3 of 3
Asifa Malik, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome,

Asifa Malik, MD, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Susan o'Brien, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Deborah A. Thomas, MD, Elizabeth M Burton, Elias Jabbour, Jorge E. Cortes
Journal: Blood
Blood (2011) 118 (21): 3786.
https://doi.org/10.1182/blood.V118.21.3786.3786
Published: 2011
Journal Articles

Decitabine and Gemtuzumab Ozogamicin In Patients with Advanced Myelofibrosis

Ali Al-Ameri Al-Ameri, MD, Hagop Kantarjian, MD, Asifa Malik, MD, Xavier Badoux, MD, Michael Andreeff, MD, PhD, Alfonso Quintas-Cardama, MD, Gautam Borthakur, MD
Journal: Blood
Blood (2010) 116 (21): 5061.
https://doi.org/10.1182/blood.V116.21.5061.5061
Published: 2010
Journal Articles

Clinical Significance of Cardiac Co-Morbidities and Risk Factors for Patients Treated with Imatinib.

Asifa Malik, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Gloria Mattiuzzi, MD, Gloria Iliescu, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Tapan Kadia, MD, Susan O'Brien
Journal: Blood
Blood (2010) 116 (21): 4490.
https://doi.org/10.1182/blood.V116.21.4490.4490
Published: 2010